Bp Plc trimmed its holdings in shares of Allergan plc (NYSE:AGN) by 58.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 36,000 shares of the company’s stock after selling 50,000 shares during the quarter. Bp Plc’s holdings in Allergan were worth $4,811,000 as of its most recent filing with the SEC.
A number of other large investors have also added to or reduced their stakes in AGN. Vigilant Capital Management LLC increased its holdings in Allergan by 16.2% in the 4th quarter. Vigilant Capital Management LLC now owns 581 shares of the company’s stock valued at $78,000 after buying an additional 81 shares during the period. Wright Investors Service Inc. boosted its stake in shares of Allergan by 2.2% in the 4th quarter. Wright Investors Service Inc. now owns 3,862 shares of the company’s stock valued at $516,000 after purchasing an additional 83 shares in the last quarter. OLD Second National Bank of Aurora boosted its stake in shares of Allergan by 1.4% in the 4th quarter. OLD Second National Bank of Aurora now owns 5,962 shares of the company’s stock valued at $797,000 after purchasing an additional 84 shares in the last quarter. Beaton Management Co. Inc. boosted its stake in shares of Allergan by 5.6% in the 3rd quarter. Beaton Management Co. Inc. now owns 1,891 shares of the company’s stock valued at $361,000 after purchasing an additional 100 shares in the last quarter. Finally, Pflug Koory LLC boosted its stake in shares of Allergan by 17.4% in the 4th quarter. Pflug Koory LLC now owns 709 shares of the company’s stock valued at $95,000 after purchasing an additional 105 shares in the last quarter. 84.04% of the stock is currently owned by institutional investors and hedge funds.
A number of equities research analysts have recently weighed in on the stock. Wells Fargo & Co restated an “outperform” rating and issued a $202.00 price target (down from $217.00) on shares of Allergan in a research note on Wednesday. Royal Bank of Canada downgraded shares of Allergan from an “outperform” rating to a “sector perform” rating and set a $165.00 price target on the stock. in a research note on Wednesday, January 30th. Credit Suisse Group downgraded shares of Allergan from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $197.00 to $161.00 in a research note on Thursday, January 31st. ValuEngine downgraded shares of Allergan from a “sell” rating to a “strong sell” rating in a research note on Tuesday, January 29th. Finally, Mizuho reduced their price target on shares of Allergan to $200.00 and set a “buy” rating on the stock in a research note on Wednesday, January 30th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have assigned a buy rating to the stock. Allergan currently has a consensus rating of “Hold” and a consensus target price of $199.79.
In other news, CFO Matthew M. Walsh purchased 1,000 shares of the company’s stock in a transaction dated Friday, November 16th. The shares were purchased at an average price of $157.00 per share, for a total transaction of $157,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.37% of the stock is currently owned by insiders.
NYSE:AGN opened at $140.33 on Thursday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.34 and a current ratio of 1.51. Allergan plc has a one year low of $125.84 and a one year high of $197.00. The company has a market cap of $46.16 billion, a P/E ratio of 8.41, a price-to-earnings-growth ratio of 1.05 and a beta of 1.43.
Allergan (NYSE:AGN) last posted its earnings results on Tuesday, January 29th. The company reported $4.29 EPS for the quarter, topping the consensus estimate of $4.15 by $0.14. The business had revenue of $4.08 billion for the quarter, compared to the consensus estimate of $4 billion. Allergan had a negative net margin of 32.28% and a positive return on equity of 8.18%. The firm’s revenue was down 5.7% compared to the same quarter last year. During the same period last year, the company earned $4.86 EPS. On average, analysts expect that Allergan plc will post 16.34 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, March 15th. Stockholders of record on Friday, February 15th will be given a $0.74 dividend. The ex-dividend date is Thursday, February 14th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 2.11%. This is an increase from Allergan’s previous quarterly dividend of $0.72. Allergan’s payout ratio is 17.26%.
Allergan declared that its Board of Directors has initiated a share buyback program on Tuesday, January 29th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the company to reacquire up to 4.1% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its shares are undervalued.
Allergan Company Profile
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.
Further Reading: Debt-To-Equity Ratio
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.